Quality of life, satisfaction, adherence and effectivity to antiviral treatment;Calidad de vida, satisfacción, adherencia y efectividad del tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 10, 2005, Pages 579-580

  Knobel, Hernando ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 29444435405     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0213-005x(05)75035-7     Document Type: Editorial

References (14)

1. WHOQOL GROUP. Measuring quality of life: the development of the World Health Organization Quality of Life Instrument (WHOQOL). En: Bowling A, editor. Measuring health: A review of quality of life measurement scales. Buckingham: Open University Press; 1997.
2. Badia X. La satisfacción con el tratamiento. Med Clin (Barc). 2005;125:98-9.
3. Ruiz Pérez I, Olry de Labry A, López Ruz MA, Del Arco Jiménez A, Rodríguez Baño J, Causse Prados M, et al. Estado clínico, adherencia al TARGA y calidad de vida en pacientes con infección por VIH tratados con antirretrovirales. Enferm Infecc Microbiol Clin. 2005;23:581-5.
4. Badia X, Podzamczer D, López-Lavid C. Medicina basada en la evidencia y la validación de cuestionarios de calidad de vida. La versión española del MOS-HIV para la evaluación de la calidad de vida en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin. 1999;17 Supl 2:103-13.
5. Muni R, Fantoni M, Del Borgo C, Visona R, Barraco A, Zambelli A, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care. 2003;15:581-90.
6. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17:10-22.
7. Fumaz CR, Tuldrá A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence oh HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-53.
8. Casado A, Badia X, Consiglio E, Ferrer E, González A, Pedrol E, et al. Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapineassociated with ZDV/3TC (the COMBINE -QoL, substudy). HIV Clin Trials. 2004;5:132-9.
9. Van Leth F, Conway B, Laplumé H, Martin D, Fisher M, Jelaska A, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antiviral Therapy. 2004;9:721-8.
10. Clotet B, Carmena J, Pulido F, Luque I, Rodríguez-Alcántara F, COL30494 Cohort Study Members. Adherence, quality of life, and general satisfaction- with co-formulated zidovudine, lamivudine and abacavir on antiretroviral-experienced patients. HIV Clin Trials. 2004;5:33-9.
11. True A, DeMasi R, Falcon R. Evaluation of HIV-patient quality of life and tolerability after administration of enfuvirtide-based HAART using smaller needle in a community practice setting (QUALITÉ). 3rd IAS Conference on HIV Pathogenesis and Treatment. Brazil: Rio de Janeiro; July 24-27 2005. Abstract: WePe 6.3C09.
12. Condes E, Aguirrebengoa K, Dalmau D, Estrada V, Force L, Górgolas M, et al. Validación de cuestionario de satisfacción com el tratamiento antiretroviral: cuestionario CESTA. Enferm Infecc Microbiol Clin. 2005;23:586-92.
13. Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment HIV infection: patient satisfaction and implication for adherence. AIDS Patients Care STDS. 2005;19:9-18.
14. Preau M, Leport C, Salmon-Ceron D, Carrieri P, Portier H, Chene G, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care. 2004;16:649-61.